Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Proactive's Thomas Warner after announcing the dosing of the first patient in a new trial of the company's AT278 ultra-concentrated and rapid-acting insulin.
Howell explains what the trial means for Arecor as it works towards developing better solutions for people living with diabetes.